Xcout Intel
CAMBRIDGE COGNITION HOLDINGS PLC
Cambridge Cognition Holdings Plc is a neuroscience technology company focused on developing and globally marketing sophisticated cognitive testing solutions for use in clinical settings. The firm operates internationally, serving clients in the United States, United Kingdom, and European Union, among other regions. Its extensive product portfolio includes CANTAB Recruit, an online platform designed to help pharmaceutical and biotechnology companies efficiently identify and onboard eligible participants for clinical trials, particularly in high-need therapeutic areas such as Alzheimer's disease. For broader pharmaceutical research, CANTAB Connect offers digital cognitive assessment tools applicable across all clinical trial phases (I-IV) and various medical fields. Additionally, the Cognition Kit is a digital health platform that utilizes wearable and smartphone applications to collect data, aiming to boost patient involvement, validate treatment efficacy, and deepen understanding of diseases and individual responses to medication. Other specialized offerings include CANTAB Connect Research, advanced software providing precise digital metrics for cognitive function in brain research; CANTAB Mobile, a touchscreen memory test frequently used in clinical studies pertaining to Alzheimer's disease; and CANTAB BrainHealth, an online digital assessment tool for monitoring mental well-being and cognitive performance in professional environments. The company also provides CANTAB Insight, a medical device for evaluating an individual's cognitive health, and NeuroVocalix, a secure platform enabling automated administration and scoring of validated verbal cognitive assessments. Beyond its technological products, Cambridge Cognition furnishes a suite of expert consultancy and operational management services tailored to enhance clinical trials and cognitive research. These services encompass neuroscience and technical advice, study design, data analysis, comprehensive study and data management, and the provision of insightful reports and interpretations. Cambridge Cognition Holdings Plc was established in 2012 and is headquartered in Cambridge, United Kingdom.
Subscribe to see CAMBRIDGE COGNITION HOLDINGS PLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
CAMBRIDGE COGNITION HOLDINGS PLC at a glance
CAMBRIDGE COGNITION HOLDINGS PLC is a healthtech company headquartered in Cambridge, United Kingdom, founded in 2012. It is publicly listed (COG) with a market capitalisation of $24.1M.
CAMBRIDGE COGNITION HOLDINGS PLC competitors
A few of CAMBRIDGE COGNITION HOLDINGS PLC's closest competitors — see the full list of competitors and alternatives →
Melbourne, Australia-based Cogstate Limited, established in 1999, is a neuroscience technology company specializing in computerized cognitive assessments and digital solutions for clinical outcome evaluations. Its comprehensive suite of cognitive services includes project and data management, scientific consulting, statistical analysis, procurement of assessment scales, rater training, and monitoring solutions. The company operates through two distinct divisions. The Clinical Trials segment delivers technology and support services designed to measure the impact of diseases, pharmaceuticals, medical devices, or other interventions on human participants in clinical studies, primarily serving pharmaceutical and biotechnology clients. Concurrently, its Healthcare segment offers Cognigram, a system facilitating regular and standardized testing to assist primary care physicians and hospitals in the early identification of cognitive decline. By June 30, 2022, Cogstate had participated in an estimated 1,800 academic research initiatives.
Cumulus Neuroscience is a UK neurotechnology company that develops wearable EEG headsets and associated software for measuring brain activity and cognitive function. Its products are intended primarily for pharmaceutical and biotechnology companies conducting clinical trials and developing treatments for neurological and psychiatric disorders.
Beacon Biosignals is a healthtech company that uses EEG data, digital biomarkers, and machine learning to characterize brain activity and support neuroscience research and clinical drug development. It serves pharmaceutical and biotechnology companies, academic researchers, and clinical-trial teams working on neurological and psychiatric disorders.
Indivi AG is a biotechnology research company headquartered in Basel, Switzerland. It focuses on pioneering the future of precision neurology through digital biomarkers for clinical research and patient monitoring, dedicated to unlocking the potential of digital measurements in drug development.
Qureight is a UK healthtech company that develops a cloud-based platform for organizing and analyzing complex clinical and biomedical data, including imaging and other multimodal datasets. It serves pharmaceutical and biotechnology companies, healthcare researchers, and clinical organizations working on disease research and drug development.
Winterlight Labs Inc., founded in 2015 and headquartered in Toronto, Canada, offers innovative cognitive assessment solutions. The company specializes in speech analytics and digital biomarkers for assessing brain health.
Get CAMBRIDGE COGNITION HOLDINGS PLC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about CAMBRIDGE COGNITION HOLDINGS PLC? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on CAMBRIDGE COGNITION HOLDINGS PLC in Xcout Intel
- The full competitor set, tracking, exports and API access